Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
By How Much Is The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Expected To Expand Between 2025 And 2029?
The transthyretin amyloid cardiomyopathy (attr-cm) treatment market size has experienced significant expansion in recent years. This market is projected to grow from $10.36 billion in 2024 to $13.29 billion in 2025, at a compound annual growth rate (CAGR) of 28.2%. The historical growth of this market can be attributed to several factors, including the increasing prevalence of transthyretin amyloid cardiomyopathy, a rising incidence of transthyretin amyloidosis particularly among geriatric patients, enhanced awareness among both healthcare professionals and patients, and a general improvement in healthcare services alongside increased public awareness.
The transthyretin amyloid cardiomyopathy (attr-cm) treatment market size is anticipated to experience rapid expansion over the next few years. This market is projected to reach $35.5 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 27.8%. The observed growth during the forecast period stems from the increasing prevalence of transthyretin amyloidosis, a rise in the diagnosis of neuropathic disorders, the growing demographic of the aging population, an elevated demand for specific drugs to address symptoms of this rare condition, and a general increase in healthcare demand. Significant trends expected during this period involve new diagnostic technologies, the development of innovative techniques for therapy management, groundbreaking and targeted treatments for transthyretin amyloidosis, advancements in diagnostic techniques, and cardiac MRI techniques.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp
Which Drivers Are Supporting Growth Of The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
An anticipated increase in chronic disease occurrences is poised to stimulate the expansion of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in the future. These conditions are characterized by their long duration, gradual progression, and persistence for at least a year, frequently necessitating ongoing medical attention. The growing incidence of chronic diseases can be linked to several factors, including an aging global populace, inactive lifestyles, poor dietary habits, escalating obesity levels, and exposure to environmental contaminants. Treatment for transthyretin amyloid cardiomyopathy works by stabilizing transthyretin, diminishing amyloid accumulation, enhancing cardiac function, and relieving symptoms to improve the management of associated chronic conditions. As an illustration, data from September 2023 released by the World Health Organization, a specialized agency of the United Nations based in Switzerland, indicated that 41 million deaths annually, accounting for 74% of all fatalities, were attributable to non-communicable diseases (NCDs) or chronic diseases. Worldwide, cardiovascular diseases were responsible for 17.9 million deaths, cancer for 9.3 million deaths, chronic respiratory diseases for 4.1 million deaths, and diabetes for 2.0 million deaths. Consequently, the increasing occurrence of chronic diseases is a significant impetus for the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
What Are The Major Segments Identified In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The transthyretin amyloid cardiomyopathy (attr-cm) treatmentmarket covered in this report is segmented –
1) By Type: Transthyretin Stabilizers; Nonsteroidal Anti-inflammatory Drugs (NSAID); RNAi Therapy; Other Types
2) By Indication: Wild type ATTR Amyloidosis; Hereditary ATTR amyloidosis
3) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis; Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin; Ibuprofen; Other NSAIDs
3) By RNAi Therapy: Patisiran; Vutrisiran
4) By Other Types: Gene Silencing Therapies; Immunotherapy Approaches; Emerging Small Molecule Therapies
Which Market Trends Are Creating New Opportunities In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Industry?
Leading companies in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are concentrating on developing innovative therapies for ATTR-CM. These include oral prescription medications designed to target and stabilize transthyretin (TTR) proteins or reduce amyloid fibril accumulation in the heart. Oral prescription medication refers to drugs prescribed by a healthcare provider that are taken by mouth, typically in the form of tablets, capsules, or liquid solutions. For instance, in November 2024, BridgeBio Pharma Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration for Attruby (acoramidis) for the treatment of adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This stabilizes the TTR protein, leading to a reduction in heart-related deaths and hospitalizations. Clinical trials have demonstrated that it is well-tolerated and offers rapid benefits by addressing the underlying cause of the disease.
Which Major Industry Participants Are Leading The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Growth?
Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG
Download The Full Report For Exclusive Market Findings:
How Is Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Demand Varying Across Different Regions?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp
Browse Through More Reports Similar to the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market 2025, By The Business Research Company
Cardiovascular Surgery Devices And Equipment Global Market Report 2025
Cardiovascular Monitoring And Diagnostic Devices And Equipment Global Market Report 2025
Interventional Cardiology Devices And Equipment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model